Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez-Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilen MA, Choueiri TK, Harshman LC.
Abou Alaiwi S, et al. Among authors: xie w.
J Immunother Cancer. 2020 Feb;8(1):e000144. doi: 10.1136/jitc-2019-000144.
J Immunother Cancer. 2020.
PMID: 32066646
Free PMC article.